FoxM1 Is a General Target for Proteasome Inhibitors
Open accessThe DOI matches its Crossref record; 22 of the 22 references it cites were found in a registry or an index.
Abstract
Proteasome inhibitors are currently in the clinic or in clinical trials, but the mechanism of their anticancer activity is not completely understood. The oncogenic transcription factor FoxM1 is one of the most overexpressed genes in human tumors, while its expression is usually halted in normal non-proliferating cells. Previously, we established that thiazole antibiotics Siomycin A and thiostrepton inhibit FoxM1 and induce apoptosis in human cancer cells. Here, we report that Siomycin A and thiostrepton stabilize the expression of a variety of proteins, such as p21, Mcl-1, p53 and hdm-2 and also act as proteasome inhibitors in vitro. More importantly, we also found that well-known proteasome inhibitors such as MG115, MG132 and bortezomib inhibit FoxM1 transcriptional activity and FoxM1 expression. In addition, overexpression of FoxM1 specifically protects against bortezomib-, but not doxorubicin-induced apoptosis. These data suggest that negative regulation of FoxM1 by proteasome inhibitors is a general feature of these drugs and it may contribute to their anticancer properties.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
Wang, Z., Banerjee, S., Kong, D., Li, Y., & Sarkar, F. H. (2007) · Cancer Research · doi:10.1158/0008-5472.can-07-1265 · Cited by 245
RetractedIs NF-κB a good target for cancer therapy? Hopes and pitfalls
Baud, V., & Karin, M. (2009) · Nature Reviews Drug Discovery · doi:10.1038/nrd2781 · Cited by 1,061 · cited 1×
“). Abnormal NF-kB regulation has been shown in a variety of cancers leading to the transcriptional activation of genes responsible for cell proliferation, inhibition of apoptosis, angiogenesis and metastasis”
BackgroundNuclear factor-κB inhibitors as sensitizers to anticancer drugs
Nakanishi, C., & Toi, M. (2005) · Nature Reviews Cancer · doi:10.1038/nrc1588 · Cited by 724 · cited 1×
“The proteasome is a protein complex that target ubiquitin-tagged proteins for degradation in an ATP-dependent manner. Recent advances in the understanding of the mechanisms of proteasome activity led to the development of proteasome inhibitors as effective drugs against human cancer. Bortezomib (Velcade) was the first…”
BackgroundMulligan, G., Mitsiades, C., Bryant, B., Zhan, F., Chng, W. J., Roels, S., Koenig, E., Fergus, A., Huang, Y., Richardson, P., et al. (2007) · Blood · doi:10.1182/blood-2006-09-044974 · Cited by 416 · cited 1×
“Significance of NF-kB targeting by bortezomib was validated in multiple myeloma cells where genes that belong to NF-kB pathway were significantly overexpressed in samples associated with response to bortezomib [3,4].”
BackgroundFoxM1: At the crossroads of ageing and cancer
Laoukili, J., Stahl, M., & Medema, R. H. (2007) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2006.08.006 · Cited by 377 · cited 2×
“Forkhead box (Fox) M1, FoxM1, is a transcription factor of the Forkhead family that induces the expression of genes involved in cell cycle progression and maintenance of genomic stability [6].”
BackgroundKalinichenko, V. V., Major, M. L., Wang, X., Petrovic, V., Kuechle, J., Yoder, H. M., Dennewitz, M. B., Shin, B., Datta, A., Raychaudhuri, P., et al. (2004) · Genes & Development · doi:10.1101/gad.1200704 · Cited by 356 · cited 2×
“On the other hand, suppression of FoxM1 expression delayed liver tumor growth in mice [10,11] and inhibited the metastatic potential of human pancreatic cancer cells in vitro [12].”
BackgroundMethodPilarsky, C., Wenzig, M., Specht, T., Saeger, H. D., & Grützmann, R. (2004) · Neoplasia · doi:10.1593/neo.04277 · Cited by 329 · cited 1×
“. It has been shown that FoxM1 is strongly upregulated in a variety of human solid tumors (reviewed in ref.”
BackgroundIdentification of a Chemical Inhibitor of the Oncogenic Transcription Factor Forkhead Box M1
Radhakrishnan, S. K., Bhat, U. G., Hughes, D. E., Wang, I.-C., Costa, R. H., & Gartel, A. L. (2006) · Cancer Research · doi:10.1158/0008-5472.can-06-1576 · Cited by 234 · cited 10×
“To further examine the role of FoxM1 in apoptosis induced by proteasome inhibitors we utilized a U2OS-C3-osteosarcoma cell line with a doxycycline-inducible FoxM1-GFP fusion protein [13] and tested how proteasome inhibitors induce cell death in the presence and the absence of exogenous FoxM1.”
BackgroundMethodSelf-citationMartin, K. J., Patrick, D. R., Bissell, M. J., & Fournier, M. V. (2008) · PLoS ONE · doi:10.1371/journal.pone.0002994 · Cited by 224 · cited 1×
“The role of FoxM1 in promoting cancer was further emphasized by the poor prognosis for breast cancer patients with higher levels of FoxM1 gene expression [9].”
BackgroundProteasome inhibitors: antitumor effects and beyond
Nencioni, A., Grünebach, F., Patrone, F., Ballestrero, A., & Brossart, P. (2007) · Leukemia · doi:10.1038/sj.leu.2404444 · Cited by 220 · cited 2×
“Since proteasome inhibitors usually hinder the activity of NF-kB via the stabilization of its negative regulator IkB-a [1,2] we examined whether Siomycin A and thiostrepton inhibit NF-kB activity.”
BackgroundResult
Cited by
Arnison, P. G., Bibb, M. J., Bierbaum, G., Bowers, A. A., Bugni, T. S., Bulaj, G., Camarero, J. A., Campopiano, D. J., Challis, G. L., Clardy, J., et al. (2013) · Nat. Prod. Rep. · doi:10.1039/c2np20085f · Cited by 2,076
Nogueira, V., & Hay, N. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-1424 · Cited by 514
FOXM1: From cancer initiation to progression and treatment
Koo, C.-Y., Muir, K. W., & Lam, E. W.-F. (2012) · Biochimica et Biophysica Acta (BBA) - Gene Regulatory Mechanisms · doi:10.1016/j.bbagrm.2011.09.004 · Cited by 406
ROS inhibitor N-acetyl-L-cysteine antagonizes the activity of proteasome inhibitors
Halasi, M., Wang, M., Chavan, T. S., Gaponenko, V., Hay, N., & Gartel, A. L. (2013) · Biochemical Journal · doi:10.1042/bj20130282 · Cited by 366
Self-citationProteasome inhibitors in cancer therapy
Crawford, L. J., Walker, B., & Irvine, A. E. (2011) · Journal of Cell Communication and Signaling · doi:10.1007/s12079-011-0121-7 · Cited by 299
The transcription factor FOXM1 is a cellular target of the natural product thiostrepton
Hegde, N. S., Sanders, D. A., Rodriguez, R., & Balasubramanian, S. (2011) · Nature Chemistry · doi:10.1038/nchem.1114 · Cited by 269
FOXM1 in Cancer: Interactions and Vulnerabilities
Gartel, A. L. (2017) · Cancer Research · doi:10.1158/0008-5472.can-16-3566 · Cited by 222
“HSP70 inhibits FOXM1 activity and expression Previously, we showed that proteasome inhibitors suppress FOXM1 transcriptional activity, and as a result of the FOXM1 positive autoregulatory loop (26), they also inhibit FOXM1 mRNA and protein expression (14, 15).”
BackgroundSelf-citationDeregulation of the Hippo pathway in soft-tissue sarcoma promotes FOXM1 expression and tumorigenesis
Eisinger-Mathason, T. S. K., Mucaj, V., Biju, K. M., Nakazawa, M. S., Gohil, M., Cash, T. P., Yoon, S. S., Skuli, N., Park, K. M., Gerecht, S., et al. (2015) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1420005112 · Cited by 103
Novel functions of FoxM1: from molecular mechanisms to cancer therapy
Alvarez-Fernández, M., & Medema, R. H. (2013) · Frontiers in Oncology · doi:10.3389/fonc.2013.00030 · Cited by 85
Puig-Butille, J. A., Vinyals, A., Ferreres, J. R., Aguilera, P., Cabré, E., Tell-Martí, G., Marcoval, J., Mateo, F., Palomero, L., Badenas, C., et al. (2017) · Journal of Investigative Dermatology · doi:10.1016/j.jid.2017.01.021 · Cited by 58
“Thus, we conducted in vivo treatments with Bortezomib, which inhibits FOXM1 transcriptional activity and expression (Bhat et al. 2009; Gartel 2010).”
MethodTargeting of the FOXM1 Oncoprotein by E3 Ligase-Assisted Degradation
Luo, G., Lin, X., Vega-Medina, A., Xiao, M., Li, G., Wei, H., Velázquez-Martínez, C. A., & Xiang, H. (2021) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.1c01069 · Cited by 56
Nicolson, S. C., Li, C., Hirsch, M. L., Setola, V., & Samulski, R. J. (2016) · Journal of Virology · doi:10.1128/jvi.02953-15 · Cited by 48
Metadata
- Authors
- Bhat, U. G., Halasi, M., & Gartel, A. L.
- Venue
- PLoS ONE
- Publisher
- Public Library of Science (PLoS)
- Published
- 2009-08-12
- Volume
- 4
- Issue
- 8
- Pages
- e6593
- ISSN
- 1932-6203 (ISSN-L)
- OpenAlex
- W1970041667
- Cited by
- 185
- References
- 22
- FWCI
- 5.64
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.